Award notice · Contracts Finder
NHS Pharmaceuticals 2017_2
Part of NHS Pharmaceuticals 2017_2.
NHS Pharmaceuticals 2017_2. Period of framework agreement: The total maximum duration of the framework agreement to be no more than 36 months. Potential periods of call-offs under the framework agreement: CESW regions: 1.8.2018 to 28.2.2019 (7 months). NWLN regions: 1.8.2018 to 31.7.2019 (12 months). LSNE regions: 1.8.2018 to 31.1.2020 (18 months). Products on the framework include (but are not necessarily limited to): Abacavir, Abiraterone, Anidulafungin, Atovaquone, Bosentan, Ciclesonide, Drospirenone/Ethinylestradiol, Enfurvitide, Ethinylestradiol/Norelgestromin, Exenatide, Ezetimibe…
- Procurement
- NHS Pharmaceuticals 2017_2
- Buyer
- NHS England
- Published
- 21 May 2018
- Status
- complete
- CPV
- 33600000 — Pharmaceutical products
- Tender period
- — – 26 Jan 2018
Awards
Other notices in this procurement
This is the only notice on record.
FAQs about this notice
What type of notice is this?
This is a award notice published via Contracts Finder on 21 May 2018.
Which procurement does this notice belong to?
It is part of "NHS Pharmaceuticals 2017_2", published by NHS England.
Has this notice resulted in an award?
1 award is recorded on this notice, including to Please see list of awarded suppliers (including SME status) at t.
Get the full procurement picture
Enable turns the UK's public-contract data into pipeline intelligence for bid and capture teams. Talk to us about access, alerts and tailored market analysis.
Get in touch with Enable